Retatrutide: Three Receptors, Still Investigational

The short version

Retatrutide — also designated LY3437943 — is a GIP/GLP-1/glucagon receptor triple agonist in Phase 3 clinical development by Eli Lilly. It has not been approved by the FDA or any regulator as of mid-2026. All efficacy and safety figures cited here come from Phase 1 and Phase 2 clinical trials; Phase 3 (TRIUMPH) results are not yet available.

In a 48-week Phase 2 obesity trial, once-weekly retatrutide at 12 mg produced a mean -24.2% body weight change versus -2.1% with placebo ^[15]. In a Phase 2 trial in type 2 diabetes, 12 mg lowered HbA1c by -2.02% at 24 weeks and reduced body weight by 16.94% at 36 weeks ^[16]. A Phase 2 substudy in metabolic liver disease (MASLD) found 86% of participants reached normal liver fat at 24 weeks at the highest dose ^[14].

Adding glucagon receptor agonism to the GIP/GLP-1 combination is the key pharmacological distinction: glucagon receptor activation increases energy expenditure through a thermogenic mechanism, complementing the appetite suppression of the other two arms. This page summarizes published data only; it contains no advice and no recommended dose.

What it is

Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, acylated with a C20 fatty diacid arm for albumin binding and extended half-life enabling once-weekly subcutaneous administration. Molecular formula C221H342N46O68 (free acid).

It is a triple agonist: a single molecule activating three receptors. Cryo-EM structures published in 2024 resolved how it engages all three — GLP-1R, GIPR, and GCGR — at atomic resolution. Relative to endogenous hormones it is approximately 8.9-fold more potent at the GIP receptor but 0.3-fold and 0.4-fold at the glucagon and GLP-1 receptors respectively; the ECL1 loop adopts different conformations at each receptor (rigid alpha-helix at GLP-1R and GCGR; flexible loop at GIPR) ^[13]. This structural heterogeneity reflects a molecule designed to engage three receptors differentially, not uniformly.

How it works

Retatrutide inherits the appetite-suppression and insulin-secretion pharmacology of GLP-1 and GIP agonism, and adds controlled glucagon receptor stimulation. Glucagon normally signals the liver to release stored glucose — the same hormone responsible for the hypoglycemia counter-regulation that GLP-1 agonists have to partially suppress. In the context of simultaneous GLP-1/GIP-mediated insulin augmentation, however, mild glucagon receptor agonism instead acts to increase energy expenditure through brown-adipose-tissue thermogenesis and fatty-acid oxidation, with minimal net glucose elevation.

The combination therefore works on both sides of the energy equation: the GLP-1/GIP arms suppress intake (eating less), while the glucagon arm boosts expenditure (burning more). A 2025 review characterizes this as a step-change versus prior incretin therapies, with Phase 1/2 weight loss reaching ~24% described as qualitatively different from the ~15-20% typically achieved with dual agonism alone ^[12]. The cardiovascular and kidney implications of this three-receptor pharmacology are being evaluated in dedicated ongoing trials.

What the research shows

Triple-agonist pharmacology — structural basis. A 2024 cryo-EM study resolved retatrutide's engagement of all three receptor complexes (GLP-1R, GIPR, GCGR) at 2.68, 3.26, and 2.84 Å resolution respectively, confirming the triple-agonist binding and characterizing the relative potencies: ~8.9-fold above native GIP at GIPR but 0.3-fold and 0.4-fold at GCGR and GLP-1R versus endogenous hormones ^[13].

Phase 2 obesity trial. In 338 adults with obesity across 48 weeks, once-weekly retatrutide at 12 mg produced -24.2% mean body weight versus -2.1% with placebo. GI adverse events were dose-related and mostly mild-to-moderate; a dose-dependent heart-rate increase peaking around 24 weeks was observed ^[15].

Phase 2 type 2 diabetes trial. In 281 adults with type 2 diabetes over 36 weeks, retatrutide 12 mg lowered HbA1c by -2.02% versus -0.01% with placebo at 24 weeks and reduced body weight by 16.94% versus 3.00% placebo at 36 weeks. GI adverse events occurred in 35%; no severe hypoglycemia and no deaths were reported ^[16].

Phase 2 metabolic liver disease (MASLD) substudy. In 98 adults with obesity or overweight and MASLD (≥10% liver fat confirmed by MRI-PDFF, no type 2 diabetes), retatrutide 12 mg reduced relative liver fat by -82.4% at 24 weeks; 86% of participants reached normal liver fat (<5%). Reductions were sustained to 48 weeks (-86.0% at 12 mg) ^[14].

Narrative review of Phase 1/2 program. A 2025 review synthesizes the triple-agonist pharmacology and available trial data, characterizing the ~24% weight loss observed at 12 mg/48 weeks as a step-change versus prior incretin agents, reviews the glucagon-driven energy-expenditure hypothesis, describes the GI and heart-rate safety profile, and notes the ongoing Phase 3 TRIUMPH program ^[12].

Reported effects, cautions & safety

People using retatrutide for research purposes in peptide communities describe a profile broadly consistent with the GLP-1/GIP class, with some unique features attributed to the glucagon arm. These are compiled from online community reports and are explicitly anecdotal — no clinical oversight, no verified doses.

Reported benefits (anecdotal, not clinical findings): Near-total silencing of food-related thoughts — "food noise going quiet" — is the most consistent theme, described as even more complete than with other incretin-class compounds. Rapid and pronounced weight reduction is frequently reported, broadly aligned with the Phase 2 trial trajectory. A distinct warmth or mild thermogenic sensation — feeling warmer, sweating more easily — is commonly noted and widely attributed in community discussion to the glucagon receptor arm. Mood uplift and a lighter relationship with food are occasionally described.

Reported adverse effects (anecdotal, not clinical findings): Nausea in the hours after injection is the most common complaint, described as peaking 4-8 hours post-dose and most prominent during initial weeks. An elevated resting heart rate — with some users observing 5-15 bpm increases on wearables — is a recurring theme and maps to the dose-dependent heart-rate elevation documented in Phase 2. Sulfur burps, constipation, early-phase fatigue, and occasional injection-site itching are also described.

Cited cautions from the clinical literature:

• Investigational status / unverified supply: Retatrutide is not approved. Material obtained outside a clinical trial cannot be confirmed to contain authentic retatrutide at stated concentration; independent analyses of similar gray-market peptides have identified truncated sequences, racemized amino acids, or different compounds altogether; the FDA issued over 50 warning letters to retatrutide vendors in 2025 ^[12].
• Gastrointestinal intolerance: Nausea affected up to 45% of participants at the highest Phase 2 dose and drove an 18% discontinuation rate at that level; without clinical dose-escalation oversight, GI severity, dehydration, and electrolyte imbalance risks are unmanaged ^[15].
• Dose-dependent heart-rate increase: Phase 2 data show mean increases of approximately 5-7 bpm at the highest doses, peaking around 24 weeks; the glucagon receptor drives cardiac chronotropy via cAMP/PKA signaling. A dedicated cardiovascular outcomes trial (NCT06383390) is ongoing and has not reported results ^[15].
• Hypoglycemia with insulin or sulfonylureas: GLP-1 and GIP agonism augments insulin secretion; combined with exogenous insulin or sulfonylureas, this can drive glucose below safe thresholds without clinical monitoring to detect or correct it ^[16].
• Lean-mass loss: Phase 2 body-composition data confirm absolute reductions in lean mass alongside fat; the 2025 Lancet Diabetes & Endocrinology substudy in type 2 diabetes characterizes the fat-to-lean ratio as more favorable than historic bariatric benchmarks but notes clinically meaningful lean loss in rapid-loss contexts ^[12].
• Long-term safety unknown: TRIUMPH-1/2/3, the cardiovascular outcomes trial (NCT06383390), and the dedicated kidney trial (NCT05929066) are ongoing; no long-term outcomes data exist. Phase 2 trial durations capture 36-48 weeks; effects and safety beyond that window are uncharacterized ^[12].

Where it fits in metabolic research

Retatrutide is the frontier on this desk — the molecule that extends the incretin agonism ladder to a third receptor and, in Phase 2 data, achieved weight loss figures (-24.2% at 48 weeks) that exceed those of both semaglutide (-14.9% at 68 weeks in STEP 1 ^[4]) and tirzepatide (-20.9% at 72 weeks in SURMOUNT-1 ^[8]). The pattern across the three compounds is consistent: each additional receptor arm has, so far, translated to greater weight reduction. The missing pieces for retatrutide are long-term outcomes data, regulatory approval, and Phase 3 confirmation of the Phase 2 signal. It is genuinely the most promising and the most uncertain compound on this desk simultaneously. See the comparison page for the side-by-side.